Clinical trials: PET-CT
Prostate Cancer
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate Specific Antigen (PSA) levels.
- Trial name
- NCT04794777
- Testing
- Individualised therapy, Standard salvage therapy
- Where
- 5 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Stefan Carlsson
Multiple Myeloma
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in MM.
- Trial name
- NCT05364177
- Testing
- 68Ga-Pentixather, 68Ga-Pentixafor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Solid Tumor, Breast Cancer
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Phase I study to evaluate the human safety and tolerability, biodistribution and dosimetry of 68GaNOTA-Anti-MMR-VHH2 Phase IIa study to evaluate tumour uptake of 68Ga-NOTA-anti-MMR-VHH2 in patients with breast cancer or melanoma.
- Conditions
- Malignant Solid Tumor, Breast Cancer, Melanoma (Skin)
- Trial name
- NCT04168528
- Testing
- 68GaNOTA-Anti-MMR-VHH2
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Universitair Ziekenhuis Brussel
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Neoplasms
68Ga-P3 PET/CT Imaging in Malignancy
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a…
- Trial name
- NCT05887687
- Testing
- [68Ga]P3
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06754085
- Testing
- Florastamin[18F] Injection
- Where
- China
- Volunteers
- 131 people
- Sponsor
- HTA Co., Ltd.
Non Small Cell Lung Cancer
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
- Trial name
- LIFE (NCT06107608)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 58 people
- Sponsor
- Jules Bordet Institute
Metastatic Clear Cell Renal Cell Carcinoma
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be…
- Trial name
- NCT06428708
- Testing
- [18F] PSMA-1007 PET/CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
Coronary Artery Disease
xSPECT-based Myocardial Perfusion Scintigraphy: Consistency of Functional Values and Feasibility of Myocardial Uptake Quantitation in Patients With Suspected Coronary Artery Disease
This study is to evaluate the feasibility of myocardial Standardized Uptake Volume (SUV) assessment by means of X- (Single photon emission tomography) SPECT/Computed tomography (CT), to assess normal reference value under rest…
- Trial name
- xSPECT MPI (NCT04583787)
- Testing
- 99mTc-sestamibi myocardial perfusion SPECT, 82Rb-Chloride myocardial perfusion PET with CCTA
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- University Hospital, Basel, Switzerland
Lung Cancer, Melanoma
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09 PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients…
- Conditions
- Lung Cancer, Melanoma, PD-L1, PET/CT
- Trial name
- NCT05156515
- Testing
- 68Ga-THP-APN09
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Oligometastatic Breast Carcinoma, Radiomics
FDG PET/CT Radiomics for True Oligometastatic Breast Cancer
FDG PET CT Radiomics for True Oligometastatic Breast Cancer
- Trial name
- NCT07872332
- Volunteers
- 100 people
- Sponsor
- Sohag University
Pre-malignant, Malignant
Prospective Evaluation of Diagnostic Performance of PanTum Detect Test in Adult Patients With Suspected or Confirmed Macroscopic Solid Pre-malignant or Malignant Lesion(s) Referred to Fludeoxyglucose (18F) PET/CT and in Adult Healthy Population
This prospective phase II trial aims to evaluate the diagnostic performance of multi-cancer epitope diagnosis in monocyte (EDIM) based blood test PanTum detect test for early detection of individuals with pre-malignant or…
- Trial name
- PanTumPET (NCT06842615)
- Testing
- Pantum detect test
- Where
- Slovakia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Comenius University
Melanoma, Merkel Cell Carcinoma, Unspecified
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- iPREDICT (NCT05013099)
- Testing
- zirconium Zr 89 crefmirlimab berdoxam
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 70 people
- Sponsor
- ImaginAb, Inc.
Malignant Neoplasm of Lung
Single Pulmonary Nodule Investigation
A small proportion of patients with lung cancer present with a solitary pulmonary nodule (SPN). This is an important group of patients because if it is lung cancer, presentation as a SPN represents early disease, which following…
- Trial name
- SPUtNIk (NCT02013063)
- Where
- 9 sites in United Kingdom
- Volunteers
- 375 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Tumor-Induced Osteomalacia
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
This is an open-label whole-body PET/CT study for investigating the value of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with Tumor-induced osteomalacia.
- Trial name
- NCT04689893
- Testing
- 68Ga-Dotatate, 68Ga-DOTA-JR11
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Non-small-cell Lung Cancer
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
The subject is going to use 18F-FDG PET/CT to assess different genetic NSCLC metabolism after cisplatin chemotherapy and targeted therapy, define the assessment criteria for the role of 18F-FDG PET/CT in NSCLC treatment respone…
- Trial name
- NCT02938546
- Testing
- 18F-FDG
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Fibroblast Activation Protein Inhibitor, PET/CT
68Ga-FAPI PET/CT in Malignant Tumors
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms.
- Conditions
- Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
- Trial name
- NCT05034146
- Testing
- 68Ga-FAPI, PET/CT
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Diabetic Foot Infection
Comparison of FDG PET and Bone Scintigraphy/Labelled Leukocyte/Gallium Scintigraphy in Diabetic Foot Osteomyelitis
Diabetic foot osteomyelitis is a common and serious complication of diabetes. While the diagnosis of soft tissue infection can be made with simple physical examination in most cases, bone involvement can be harder to diagnose…
- Trial name
- NCT03712046
- Testing
- 18F-FDG PET-CT
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Aortic Aneurysm, Abdominal, Carotid Atherosclerosis
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
Stroke and abdominal aortic aneurysms (AAAs) are common and highly lethal vascular diseases. Angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and AAAs.
- Trial name
- NCT02995642
- Testing
- 18F-FPPRGD2, Positron emission tomography, Computed tomography
- Where
- United States
- Sponsor
- Stanford University
Microglial Cells Activation Imaging
Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714
There is accumulating evidence suggesting that inflammatory processes, through microglial activation, would play a key role in brain injury and degeneration.
- Trial name
- NCT04171882
- Where
- 2 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Weibing Miao, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.